Latest articles
Articles are written for an informed general audience — patients, clinicians, and anyone who wants to navigate the peptide therapy space with accurate information rather than hype.
Not always. FDA labels for semaglutide and tirzepatide don't require a set lab panel, but clinicians may order labs based on your history. Here's what they look at.
Read articleCash-pay online GLP-1 care can include licensed clinician review, labs when needed, and follow-up—not grey-market vials. Here's how the model works.
Read articleGHK-Cu is a copper-binding tripeptide studied for skin quality. Topical cream pathway, evidence, FDA status, and clinician review.
Read articleTretinoin is a prescription topical retinoid for acne and photoaging goals. Cream vs gel, OTC retinol differences, and clinician review.
Read articleNAD+ is a coenzyme cells use for energy and DNA-repair signaling. This guide covers evidence, FDA status, and how it differs from NMN or NR.
Read articleMost people regain some weight after stopping a GLP-1. This guide covers what STEP 1 and SURMOUNT-4 show, why regain is not a failure, and why stopping belongs with a clinician.
Read articlePT-141 (bremelanotide) is a melanocortin-pathway option for sexual-health goals. This guide explains what it is, the approved HSDD use, how it differs from blood-flow medicines, and what a clinician reviews.
Read articleNo. The PCAC recommended possible 503A listing for BPC-157 and TB-500 by narrow margins, but the recommendations are non-binding. As of August 2026 neither is listed or approved, and compounding remains unlawful under the current pathway.
Read articleHealth optimization is moving from chasing the next compound or hack toward connected decision-making. This piece explains the layered "health stack" — sleep, glucose, labs, wearables, and history — and why each signal is most useful in clinician-led context.
Read articleTesamorelin is the only FDA-approved GH secretagogue, but its approval is narrow. This guide separates the approved HIV-associated lipodystrophy indication from broader wellness claims and reviews the Phase 3 visceral-fat data, safety screening, and WADA status.
Read articleSermorelin has a real GHRH mechanism and pediatric clinical history, but adult wellness claims still need careful evidence grading. This guide separates GH/IGF-1 biology from outcomes.
Read articleTB-500 is one of the most discussed recovery peptides online. This guide separates thymosin beta-4 repair biology, limited systemic human evidence, WADA status, and the post-July 2026 regulatory picture.
Read articleBPC-157 is one of the most discussed recovery peptides online. This guide separates what preclinical research suggests, what early human safety data can and cannot tell us, and why FDA compounding status matters in 2026.
Read articleThe post-shortage landscape for GLP-1 medications changed fundamentally in early 2025. This plain-English guide explains the full regulatory timeline, when compounded semaglutide and tirzepatide are still legal in 2026, when they are not, and how to evaluate your options with your clinician.
Read articlePatients exploring peptide therapy face a false binary: unregulated grey-market peptides on one end, thousand-dollar-a-month brand drugs on the other. The middle path — licensed clinician oversight, 503A-compliant compounding, and evidence-based protocols — is what appropriate care actually looks like.
Read articleWe don't have an email newsletter yet — but you can follow new articles through the RSS feed. Add https://yourhealthrx.us/blog/feed.xml to any RSS reader (Feedly, NetNewsWire, Reeder, etc.) to get new posts as they publish. We publish when there's something worth saying — not on an arbitrary schedule.
Ready to go further?
Education is the starting point. If you're considering a peptide protocol, a licensed clinician in our network can evaluate your history and determine what's clinically appropriate for you — anywhere in the US.
